

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-12. (Cancelled)

13. (Previously presented) A method of treating tissue fibrosis in a mammalian subject, said method comprising administering to said subject a therapeutically effective amount of a composition comprising (a) an antibody to IL-13 or an IL-13 binding fragment of an antibody to IL-13; and (b) a pharmaceutically acceptable carrier, thereby treating tissue fibrosis in said subject.

14-15. (Cancelled)

16. (Original) The method of claim 13, wherein tissue fibrosis affects a tissue selected from the group consisting of liver, skin epidermis, skin endodermis, muscle, tendon, cartilage, cardiac tissue, pancreatic tissue, lung tissue, uterine tissue, neural tissue, testis, ovary, adrenal gland, artery vein, colon, small intestine biliary tract and gut.

17. (Original) The method of claim 16 wherein said tissue is liver.

18. (Original) The method of claim 17 wherein said fibrosis is that resulting from infection with schistosoma.

19. (Original) The method of claim 13 wherein said fibrosis is that resulting from healing of a wound.

20. (Original) The method of claim 13 wherein said wound is a surgical incision.

21. (Previously presented) A method of inhibiting formation of tissue fibrosis in a mammalian subject, said method comprising administering to said subject a therapeutically effective amount of a composition comprising (a) an antibody to IL-13 or an IL-13 binding fragment of and IL-13 antibody; and (b) a pharmaceutically acceptable carrier, thereby inhibiting formation of tissue fibrosis in said subject.

22-23. (Cancelled)

24. (Original) The method of claim 21 wherein tissue fibrosis affects a tissue selected from the group consisting of liver, skin epidermis, skin endodermis, muscle, tendon, cartilage, cardiac tissue, pancreatic tissue, lung tissue, uterine tissue, neural tissue, testis, ovary, adrenal gland, artery vein, colon, small intestine biliary tract and gut.

25. (Original) The method of claim 21 wherein said tissue is liver.

26. (Original) The method of claim 25 wherein said fibrosis is that resulting from infection with schistosoma.

27. (Original) The method of claim 21 wherein said fibrosis is that resulting from healing of a wound.

28. (Original) The method of claim 27 wherein said wound is a surgical incision.

29-30. (Cancelled)

31. (Previously presented) The method of claim 13, wherein said composition comprises an antibody to IL-13.

32. (Previously presented) The method of claim 13, wherein said composition comprises an IL-13 binding fragment of an antibody to IL-13.

33. (Previously presented) The method of claim 13, wherein said antibody antagonizes binding of IL-13 to a human IL-13bc.

34. (Previously presented) The method of claim 31, wherein said antibody antagonizes binding of IL-13 to a human IL-13bc.

35. (Previously presented) The method of claim 32, wherein said antibody antagonizes binding of IL-13 to a human IL-13bc.

36. (Previously presented) The method of claim 13, wherein said composition is administered by intravenous, cutaneous, subcutaneous, or intravenous injection.

37. (Previously presented) The method of claim 13, wherein said composition is administered by intravenous injection.

38. (Previously presented) The method of claim 34, wherein said antibody is administered for about 12 to 24 hours of continuous administration.

39. (Previously presented) The method of claim 13, wherein said composition is administered at a dose of about 0.1 μg to about 100 mg per kg body weight.

40. (Previously presented) The method of claim 13, wherein said composition is administered at a dose of about 20 μg to about 500 μg per kg body weight.

41. (Previously presented) The method of claim 21, wherein said composition comprises an antibody to IL-13.

42. (Previously presented) The method of claim 21, wherein said composition comprises an IL-13 binding fragment of an antibody to IL-13.

43. (Previously presented) The method of claim 21, wherein said antibody antagonizes binding of IL-13 to a human IL-13bc.

44. (Previously presented) The method of claim 41, wherein said antibody antagonizes binding of IL-13 to a human IL-13bc.

45. (Previously presented) The method of claim 42, wherein said antibody antagonizes binding of IL-13 to a human IL-13bc.

46. (previously presented) The method of claim 21, wherein said composition is administered by intravenous, cutaneous, subcutaneous, or intravenous injection.

47. (Previously presented) The method of claim 21, wherein said composition is administered by intravenous injection.

48. (Previously presented) The method of claim 47, wherein said antibody is administered for about 12 to 24 hours of continuous administration.

49. (Previously presented) The method of claim 41, wherein said composition is administered at a dose of about 0.1 μg to about 100 mg per kg body weight.

50. (Previously presented) The method of claim 41, wherein said composition is administered at a dose of about 20 μg to about 500 μg per kg body weight.

51. (New) The method of claim 13, wherein said antibody is a monoclonal antibody.

52. (New) The method of claim 21, wherein said antibody is a monoclonal antibody.